Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EPS (Weighted Average and Diluted) for 15 consecutive years, with $1.48 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 48.0% year-over-year to $1.48, compared with a TTM value of $4.67 through Dec 2025, up 41.95%, and an annual FY2025 reading of $4.67, up 41.95% over the prior year.
  • EPS (Weighted Average and Diluted) was $1.48 for Q4 2025 at Neurocrine Biosciences, down from $2.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.06 in Q3 2025 and bottomed at -$0.79 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is $0.73, with a median of $0.63 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 396.0% in 2024, then crashed 80.95% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.31 in 2021, then soared by 367.68% to $1.46 in 2023, then tumbled by 31.51% to $1.0 in 2024, then skyrocketed by 48.0% to $1.48 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NBIX at $1.48 in Q4 2025, $2.06 in Q3 2025, and $1.05 in Q2 2025.